Registered Users Login:
Login In Process.
Please wait, checking username and password.

Address questions about passwords, submissions, testing, registration to:

Tim Taylor
Assistant Project Director
Drug Synthesis and Chemistry Branch
E-mail: taylort4@mail.nih.gov
Phone: 240-686-4720

If you have never used our online compound submission application, you will need to register with us as an online supplier, even if you have submitted compounds to us through another method before.

New Registrations

Structures submitted through the compound submission application will be considered for testing in our in vitro anticancer screen. .

Forgot Password?

News

Currently, the NCI is not accepting submissions of compounds for NCI-60 testing submitted from investigators outside of the United States and U.S. Territories.
Effective January 4, 2024.
**Important Update** The NCI has modernized the methodology for the NCI-60 Human Tumor Cell Lines Screen
DTP has modernized the methodology for the NCI-60 Human Tumor Cell Lines Screen to 384-well plates.
  • September 30, 2023 is the last day to ship compounds for testing using the traditional 96-well platform.
  • Compounds shipped after September 30, 2023 will be tested in the modernized NCI-60 HTS384 format.
More Detail about the modernized NCI-60 HTS384 Human Tumor Cell Lines Screen.
Password reset notice.
It is important that you completely close your browser after changing passwords. If you continue to have trouble please contact Kevin McCormack (mccormackk@mail.nih.gov) for assistance.
NOTICE: CDA signatories with private e-mail addresses will no longer be acceptable.
Signatories with personal e-mail addresses will no longer be permitted. All current signatories with personal e-mail addresses have been removed from the system. This will not affect currently signed CDA’s.
Shipping Quotas
Investigators are limited to ten (10) compounds submitted per 30-day period. These ten (10) compounds may be spread over no more than five (5) packing lists per 30-day period.
Important, Please Read -- Shipping Compounds
For secure transit, and as a matter of safe handling of agents upon receipt, all compounds shipped to the National Cancer Institute - Chemotherapeutic Agents Repository for in vitro screening are required to be contained in well-sealed, glass or plastic vials that have a positive closure. Materials not in compliance with this standard will be directly disposed of upon receipt. Additionally, if a vial is received damaged and is deemed to have contaminated the package, the entire shipment may potentially be discarded as well.

In order to process agents for testing upon receipt, all vials must be labeled with the six-digit Temporary Identification (TID) assigned to the compound upon submission.

Guidelines for Small Molecule Structures for Screening.
The Guidelines for Small Molecule Structures for Screening has been updated. Please read before submitting new structures.
CDA Information
The CDA is available for review at the following link: New NCI60 Screening CDA/MTA.

Users will need to provide the name and e-mail address of a signatory from their institution who has the authority to execute the agreement. Your submission will be reviewed by DTP only after the CDA/MTA has been agreed to by your signatory. If the CDA/MTA is declined or not acted upon after 30 days, the submission request will be deleted.

This warning banner provides privacy and security notices consistent with applicable federal laws, directives, and other federal guidance for accessing this Government system, which includes (1) this computer network, (2) all computers connected to this network, and (3) all devices and storage media attached to this network or to a computer on this network.

This system is provided for Government-authorized use only.

Unauthorized or improper use of this system is prohibited and may result in disciplinary action and/or civil and criminal penalties.

Personal use of social media and networking sites on this system is limited as to not interfere with official work duties and is subject to monitoring.

By using this system, you understand and consent to the following:
  • The Government may monitor, record, and audit your system usage, including usage of personal devices and email systems for official duties or to conduct HHS business. Therefore, you have no reasonable expectation of privacy regarding any communication or data transiting or stored on this system. At any time, and for any lawful Government purpose, the government may monitor, intercept, and search and seize any communication or data transiting or stored on this system.
  • Any communication or data transiting or stored on this system may be disclosed or used for any lawful Government purpose.

Nothing in the preceding language overrides or modifies in any way the terms of the Discreet Screening Agreement"

Useful resources (Please review the information carefully before contacting the program)